EMVision Medical Devices (ASX:EMV) said ethics approval was granted for a feasibility, usability, and workflow implementation aeromedical study as well as for a first responder study during acute suspected stroke cases attended by the Melbourne mobile stroke unit for its first responder portable brain scanner device, according to a Tuesday Australian bourse filing.
The aeromedical study is a collaboration of the Royal Flying Doctor Service, South Australia Ambulance Service's emergency retrieval service MedStar, South Australia Health's Rural Support Services, the Royal Adelaide Hospital, and the Australian Stroke Alliance.
The study will look at the device's usability, reliability, functionality, workflow metrics, and other tests as necessary to meet user and international regulatory requirements. It is on track to begin recruitment during the September quarter, with study results expected to be reported in the December quarter.
The mobile stroke unit study will evaluate the use of the first responder device during pre-hospital emergency response to acute suspected stroke patients, while gathering contemporaneous ground-truth CT-scan data. The study is on track to begin during the September quarter.
The firm received a AU$400,000 non-dilutive milestone payment under the Australian Stroke Alliance project agreement for completing the "Telemedicine and Road/Air Integration" milestone.
The company's shares fell past 1% in recent Tuesday trade.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。